BioWorld

July 10, 2002

Santarus Partners Technology With TAP In Potential $100M Deal

Santarus Inc. stands to gain up to $100 million through a licensing agreement announced Tuesday with TAP Pharmaceutical Products Inc. aimed at developing a next-generation therapy for upper gastrointestinal diseases. (BioWorld Today) Read More

Elan Seeking US$1B In Asset Sale As Top Executive Departs

Staphylococcus aureus Finally Outlasted Vancomycin, But New Antibiotics Are Treating Patient

Micrologix Signs MBI 226 Deal With Fujisawa For Up To $21M

Other News To Note

AIDS Conference

Today's news in brief

BioWorld

BioWorld briefs for June 15, 2026.

Microbiota modulates the antidepressant effects of GLP-1 analogues

BioWorld Science

Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...

Ethyreal launches to treat the underlying cause of Graves’, TED

BioWorld

Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...

EHA 2026: With new lenses, a changing view on pediatric cancers

BioWorld

In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...

Microscopic image of chronic myeloid leukemia

Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid

BioWorld

Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...